Terms: = Kidney tumors AND TTL, 2410003M22Rik, 150465, ENSG00000114999, MGC46235, Q8NG68
4 results:
1. Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Gandhi KA; Joshi A; Mehta P; Gurjar M; Rane P; Sharma J; Patil A; Nookala M; Noronha V; Prabhash K; Gota V
Cancer Chemother Pharmacol; 2022 Jun; 89(6):751-759. PubMed ID: 35441269
[TBL] [Abstract] [Full Text] [Related]
2. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
[TBL] [Abstract] [Full Text] [Related]
3. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
Chae JW; Teo YL; Ho HK; Lee J; Back HM; Yun HY; Karlsson MO; Kwon KI; Chan A
Cancer Chemother Pharmacol; 2016 Sep; 78(3):623-32. PubMed ID: 27485537
[TBL] [Abstract] [Full Text] [Related]
4. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension.
Zargar-Shoshtari K; Sharma P; Espiritu P; Kurian T; Pow-Sang JM; Mangar D; Sexton WJ; Spiess PE
Urol Oncol; 2015 Mar; 33(3):112.e23-9. PubMed ID: 25555854
[TBL] [Abstract] [Full Text] [Related]
